Daniel (Dan) joined SpringWorks at the company’s launch in 2017 and is Chairman of the Board of Directors. He is currently Executive Venture Partner at GV. Since 2007, Dan has advised and served as executive chairman or member of the boards for a number of biopharmaceutical companies, including Stromedix (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), eGenesis Bio and BIND Biosciences. Dan also served as entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. He currently serves on the boards of bluebird bio, Blueprint Medicines, Translate Bio, Xilio Therapeutics, and Alpha Omega SPAC. Previously, Dan served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of ERBITUX (cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for more than 15 years. For five years, he served on the board of directors and the audit committee of U.S. Oncology, Inc. until acquisition by McKesson in 2010. Dan received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and a B.A. in mathematics from Wesleyan University.